Teos expects to absorb nearly $25 million in one-time costs for severance and termination payments. The biotech had 173 ...

Shares of biopharmaceutical company iTeos Therapeutics, Inc. (ITOS) traded 20% higher on Wednesday morning after the company ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing in ...

At that time, I noted the potential of the company advancing its anti-TIGIT drug belrestotug together with GSK plc's (GSK) PD-1/PD-L1 JEMPERLI (dostarlimab) for the targeting of previously ...

iTeos Therapeutics announced that the GALAXIES Lung-201 Phase 2 trial, assessing the combination of belrestotug and dostarlimab for lung cancer, did not meet the criteria for clinically meaningful ...

ITeos Therapeutics is throwing in the towel. | iTeos Therapeutics is throwing in the towel. Two weeks after axing its ...

GALAXIES Lung-201 trial showed ORR benefit but failed to meet PFS criteria for belrestotug combo vs. monotherapy. iTeos holds $624.3 million in cash as of March 31, 2025, with a projected runway ...

Additionally, an interim analysis of the GALAXIES H&N-202 Phase 2 trial showed a trend below the meaningful threshold for ORR in the belrestotug combination cohorts vs. dostarlimab monotherapy in ...

Shares in iTeos Therapeutics surged after the company said it would wind down operations. The stock was up 27% at $10.87 in premarket trading. Shares were already up 11% year-to-date when the market ...